The FDA is expected to approve the FOUTH COVID-19 vaccine administered to Americans aged 50 and older next week.

Covid cases in America have so far reached one of the lowest points of the pandemic, but the Food and Drug Administration (FDA) is expected to provide a measure, amid fears that the “hidden” BA. the fourth result is the vaccine dose to the oldest of Americans.

CNN reports that the FDA plans to approve a second booster dose of both the Pfizer-BioNTech and Moderna vaccines, each of which will be the fourth dose of the company’s vaccine regimen. The Centers for Disease Control and Prevention (CDC) should therefore recommend that all Americans age 50 and older receive the injection.

Once Jab is approved, any American can qualify to get it if they want, but for now, the government will only offer it to older age groups. A similar process occurred with the first booster shot, where it was recommended only to older age groups before the arrival of the Omicron variant in late 2021.

It is not yet clear whether the Americans are ready for another recall shot. The launch of the country’s booster shot has created craters in recent weeks as cases have dropped and many have looked beyond COVID-19 in hopes that the Omicron wave will be the latest in the pandemic.

Covid cases have stabilized after a winter of dramatic ups and downs. The country now has an average of 31,604 cases per day as of Monday morning, which is roughly the same as the week before.

However, there are alarming increases in certain areas of the Americas. Cases have increased 110% in Kentucky over the past two weeks, the first state to double in this period since early February. New York, along with eight other states, has seen cases rise in the past two weeks.

These cases do not turn into deaths at the same rate as before during this wave. High American vaccine coverage, combined with the relatively mild nature of the dominant variant of Omicron, managed to protect Americans from the worst outcome.

There is an average of 850 Covid deaths per day in America as of Monday morning, a 20% drop over the past week and a figure that may continue to drop.

With dwindling deaths across the country and interest and fears for the pandemic, some experts fear it may be difficult to give Americans another chance.

Not all experts believe that shooting is also necessary.

Dr. Anna Durbin is an international public health expert at Johns Hopkins University in Baltimore, Maryland, and has been critical of Pfizer, Moderna, and the White House’s attempt to launch COVID-19 booster injections before they are necessary. She told ABC last week that she doesn’t believe many Americans will benefit from the extra hits.

“I think there are very few people who need a fourth dose,” he said.

In August, as the White House planned to launch the first mass COVID-19 reinforcements, Durbin was also a critic and told DailyMail.com there was little science to back the decision.

Few Americans are already eligible for a fourth injection of COVID-19. Despite the lack of Food and Drug Administration (FDA) approval, the Centers for Disease Control and Prevention (CDC) advise people who are immunocompromised to take the extra chance now.

Only one in 30 Americans is immunocompromised and is now eligible for this fourth injection.

“Overall, it’s too soon to recommend a fourth dose except for those who are immunocompromised,” said Dr. Paul Goepfert, professor of medicine at the University of Alabama at Birmingham, at the ABC.

The next shot fires sooner than expected for fear of the stealth variant of BA, an Omicron lineage.

Named for its ability to evade detection by some sequencing methods, the “hidden” variant is believed to be the most contagious version of Covid, but is as mild as Omciron’s version of BA.1 which covered the world last year. .

According to the latest data released last week by the Centers for Disease Control and Prevention (CDC), BA.2 accounts for 35% of active Covid cases in the United States, and BA.1 is still dominant.

However, the share of BA.2 Covid infections in America is increasing, with the variant accounting for just 23% of cases in the previous week.

Moderna CEO Stephane Bancel said last week that he expects the US to see a wave from BA.2 soon, and his company’s vaccine will be needed to keep it under control.

“Many countries around the world already have some of the 4th dose tests in high risk people,” Bancel told CNBC. squeak box† “There’s a huge wave of BA.2 variants in Europe right now, as many public health experts say it should start very soon in the US.”

However, a growing list of experts says otherwise.

The nation’s leading infectious disease expert and one of the more cautious voices during the pandemic, Dr. “I wouldn’t be surprised if we see a slight increase,” Anthony Fauci said at an event in the Washington Post. This week.

“Unless something changes drastically, I don’t really see a big wave coming.”

Although the stealth variant has yet to have a major impact on the number of cases, the data from abroad quoted by Bancel raises some concern.

Some countries that have been dealing with declining cases for months, such as the UK, France and Denmark, have seen the number of infections skyrocket in the past week. Cases appear to have stabilized in these countries and growth has stalled for now.

Internationally, the World Health Organization (WHO) reported last week that there were more than 12 million cases of Covid-19 worldwide, up 7% from the previous week.

However, the death toll fell 23% to just under 33,000, another sign of the virus’s declining death toll.

The increase in cases has been concentrated entirely in the Western Pacific, where the daily number of infections increased by 23% last week. In Europe, infections stabilized after a slight 2% increase last week.

Although the number of cases has dropped and BA.2 hasn’t caused a big wave in the United States as it has in many other countries, the fourth injection of the COVID-19 vaccine has probably always been on the way.

Fauci, Bancel and Pfizer CEO Albert Bourla are among those who say an additional dose has been on the way for months, and Bourla even says annual doses will be needed over the next decade to keep the pandemic under control.

While the injections are considered safe and effective by health authorities around the world and likely saved millions of lives last year, Pfizer and Moderna’s goals in launching the vaccine are not exactly humane.

Each of the companies made billions of dollars from vaccine sales in the United States and other countries around the world.

Pfizer, its partner BioNTech and Moderna predict combined sales of the $50 billion COVID-19 vaccine will increase further this year with the approval of the fourth dose.

Both companies hope to launch vaccines for young children in the near future. Currently, Moderna’s shot is only available to adults in the United States, while Pfizer’s is for ages five and up.

Moderna on Wednesday announced that it has successfully completed Phase 2 and 3 clinical trials for the injection of COVID-19 in children aged six months to 17 years.

Injections, one quarter smaller than those for adults, were found to be approximately 40% effective in preventing infection from the Omicron variant, compared to the levels of protection it offered for adults.

Pfizer faced a number of challenges in introducing its vaccine to younger age groups. The company had to shift its Covid vaccination regimen for young children from two to three doses, as doses smaller than three micrograms were almost completely ineffective in three- and four-year-olds.

The New York City-based company has also submitted data to regulators for the Covid vaccine in children under the age of five, although the approval process was halted earlier this year.